Nuvalent, Inc. Nuvalent, Inc.

Nuvalent, Inc.

NUVL

Peringkat dalam Saham #2113
Nuvalent, Inc. is a clinical-stage biopharmaceutical firm dedicated to... Nuvalent, Inc. is a clinical-stage biopharmaceutical firm dedicated to pioneering novel therapeutic solutions for individuals battling cancer. The company's pipeline features two prominent drug candidates. One of these is NVL-520, a highly selective ROS1 inhibitor capable of penetrating the brain. This compound is specifically designed to target ROS1 fusions that possess the normal ROS1 kinase domain, and crucially, it retains activity against mutations known to confer resistance to both approved and experimental ROS1 inhibitors. NVL-520 is currently undergoing Phase I clinical evaluation. Nuvalent's second key asset is NVL-655, an ALK-selective inhibitor that also exhibits brain-penetrant properties. This therapy seeks to address significant limitations of earlier generations of ALK inhibitors (first-, second-, and third-generation), including the development of treatment resistance, central nervous system-related adverse effects, and brain metastases. NVL-655 is presently being assessed in Phase I/II clinical trials. The company was established in 2017 and is based in Cambridge, Massachusetts.
Harga Saham
$123.96
Terakhir disinkronkan: 2026-07-21
Kapitalisasi Pasar
$9.75B
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
27.56%
Negara
US
Perdagangan Nuvalent, Inc. (NUVL)

Kategori

Healthcare
Riwayat pemecahan saham untuk Nuvalent, Inc. (NUVL)
Saham Nuvalent, Inc. (simbol: NUVL) telah mengalami total 0 kali pemecahan saham.
Pemecahan saham terbaru terjadi pada Oct 21, 2026.
Satu lembar saham NUVL yang dibeli sebelum Oct 21, 2026 sekarang setara dengan 0 lembar saham NUVL.
Daftar pemecahan saham
Tahun Pemecahan Kelipatan Kelipatan Kumulatif
Tidak cukup data untuk tanggal yang disediakan.
Pemecahan saham untuk perusahaan sejenis atau pesaing
Perusahaan Jumlah pemecahan saham Kelipatan Kumulatif Negara
1 x2
US
0 -
US
1 x3
AU
0 -
CH
0 -
NL